Retina-Vitreous
2013 , Vol 21 , Num 3
Intravitreal Bevacizumab Treatment for Chronic Central Serous Chorioretinopathy Presumably Associated with Trigger Point Steroid Injection
1M.D. Asistant Professor, Onsekiz Mart University Faculty of Medicine, Department of Ophthalmology, Canakkale/TURKEY2M.D. Professor, Gazi University Faculty of Medicine, Department of Ophthalmology, Ankara/TURKEY A 48-year-old man presented with a 6-month history of decreased visual acuity (VA) in his both eyes. There wasn't any significant medical history except an application of a steroid injection for trigger point 17 months ago. Fundus examination demonstrated atrophic changes of the retinal pigment epithelium (RPE) in the central macula OU. Optical coherence tomography showed subfoveal neurosensorial detachment adjacent to RPE detachment in the right eye and macular atrophy in the left eye. Fundus fluorescein angiography was consistent with central serous chorioretinopathy (CSC). This report describes the possible benefit of intravitreal bevacizumab in the treatment of chronic CSC complicated with trigger point steroid injection. Keywords : Chronic central serous chorioretinopathy, trigger point injection, steroid, intravitreal bevacizumab